Gilead Sciences handily beat the consensus Wall Street earnings estimate for Q4. The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech stock.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 6.4% year on year to $7.57 billion. The company expects ...

Read Our Latest Analysis on Gilead Sciences Gilead Sciences Trading Down 1.8 % NASDAQ GILD opened at $104.08 on Friday. The stock’s 50-day simple moving average is $93.87 and its two-hundred day ...

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report issued on ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.6% in the company’s quarterly cash dividend, beginning in the first ...

Gilead Beats Q4 Estimates With 7% Sales Growth, Driven by HIV and Oncology. Company Projects Strong 2025 Earnings, Eyes Lenacapavir Launch for HIV Prevention. Get real-time earnings alerts before ...

Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Shares of Gilead Sciences (NASDAQ: GILD) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year ...

Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates.